10-K: Dynavax Technologies Reports Strong HEPLISAV-B Sales Growth in 2024, Advances Vaccine Pipeline

Dynavax Technologies reports a 26% increase in HEPLISAV-B product revenue for 2024, driven by market expansion and market share gains, while also advancing its shingles and plague vaccine programs.

Summary

• Dynavax Technologies Corporation reported a 26% increase in HEPLISAV-B product revenue, reaching $268.4 million for the year ended December 31, 2024.
• The increase was primarily driven by an expanding adult hepatitis B vaccine market and HEPLISAV-B market share gains in the U.S.
• HEPLISAV-B's estimated total market share in the U.S. increased to approximately 44% at the end of 2024.
• The company anticipates the U.S. hepatitis B adult vaccine market to reach over $900 million in annual sales by 2030, with HEPLISAV-B expected to achieve at least 60% market share.
• Dynavax generated $66.5 million in cash from operating activities during 2024 and ended the year with $713.8 million in cash, cash equivalents, and marketable securities.
• The company reported a net income of $27.3 million for the year ended December 31, 2024.
• Dynavax is advancing its clinical pipeline, including a Phase 1/2 trial for its shingles vaccine candidate, Z-1018, with top-line data expected in the third quarter of 2025.
• A new agreement with the U.S. Department of Defense for approximately $30.0 million will support additional clinical and manufacturing activities for its plague vaccine candidate, including a Phase 2 clinical trial expected to start in the third quarter of 2025.
• The company decided to discontinue development of its Tdap-1018 program due to a lack of differentiated commercial profile.
• Dynavax resubmitted its sBLA for HEPLISAV-B vaccination of adults on hemodialysis to the FDA in 2025.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong financial performance and pipeline advancements, but also acknowledges existing risks and challenges.

Positives

• Significant growth in HEPLISAV-B revenue and market share.
• Strong cash position and positive net income.
• Advancement of shingles and plague vaccine programs.
• Continued collaboration with the U.S. Department of Defense.
• Universal recommendation for hepatitis B vaccination in adults aged 19-59 in the U.S. by the CDC's ACIP.

Negatives

• Discontinuation of the Tdap-1018 program.
• Dependence on HEPLISAV-B for revenue generation.
• Competition from other hepatitis B vaccines.
• Uncertainty regarding future CpG 1018 adjuvant revenue.
• Reliance on third parties for manufacturing.

Risks

• Competition in the hepatitis B vaccine market.
• Uncertainty regarding coverage, pricing, and reimbursement for HEPLISAV-B.
• Potential delays or failures in clinical trials.
• Dependence on third parties for manufacturing and supply.
• Potential product liability claims.
• Regulatory risks and ongoing post-marketing obligations.
• Reliance on intellectual property rights.
• Market acceptance of HEPLISAV-B and future products.
• Potential limitations on the use of net operating loss carryforwards.
• Potential impact of healthcare reform and drug pricing scrutiny.

Future Outlook

Dynavax expects the hepatitis B adult vaccine market in the U.S. to expand to a peak of over $900.0 million in annual sales by 2030, with HEPLISAV-B expected to achieve at least 60% total market share.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.

Comparison to Industry Standards

• HEPLISAV-B competes with Engerix-B from GSK, Recombivax-HB from Merck, Twinrix from GSK, and PreHevbrio from VBI Vaccines Inc.
• The global shingles vaccine market was over $4.0 billion in 2024.
• There are multiple other shingles vaccine candidates in development including those being developed by Pfizer, BioNTech SE, Curevo Vaccine, Moderna, Inc., and others.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through HEPLISAV-B growth and pipeline development.
• Employees: Continued employment and development opportunities.
• Customers: Access to innovative vaccines.
• Suppliers: Ongoing business relationships.
• Patients: Access to improved vaccines for infectious diseases.

Next Steps

• Report top line immunogenicity and safety data for Z-1018 in the third quarter of 2025.
• Initiate a Phase 2 clinical trial for the plague vaccine candidate in the third quarter of 2025.
• Resubmit our sBLA for HEPLISAV-B vaccination of adults on hemodialysis to the FDA in 2025.

Key Dates